Since the discovery of insulin by Frederick Grant Banting in 1921, only stringent glucose control by a regimen of multiple insulin injections has prevented microvascular and macrovascular complications in Type 1 diabetic patients. Moreover, insulin treatment amongst other treatment modalities has been shown to prevent microvascular and macrovascular complications in Type-2 diabetic patients. Incidentally, as the Type-2 diabetic epidemic expands, insulin treatment is becoming one of the main treatment modalities. Not taking into consideration availability, it has been established that more frequent patient-clinic interactions improve diabetic management in both Type-1 and Type-2 patients.